Literature DB >> 2957419

Feed-back effect of growth hormone on hypothalamic opioid and somatocrinin producing neurons.

I Ganzetti, F Petraglia, I Capuano, F Rosi, W B Wehrenberg, E E Müller, D Cocchi.   

Abstract

Reportedly, most acromegalics are refractory to the growth hormone (GH)-releasing effect of central nervous system-acting stimuli. For instance, the synthetic analogue of met-enkephalin (Enk) viz. FK 33-824 fails to alter the high circulating GH levels of acromegalics. The most likely interpretation of such finding is that circulating GH disrupts, for a negative feedback effect, hypothalamic opioid function and/or GH-releasing hormone (GHRH) producing neurons, through which opioids exert their action. To address this issue, we have evaluated in intact and hypophysectomized male rats the effect of a high-dose GH regimen on the hypothalamic stores of endogenous opioid peptides, beta-endorphin (beta-EP) and met-enkephalin (met-enk). Moreover we have evaluated in intact male rats the effect of exogenous GH on median eminence (ME) GHRH stores and the ability of FK 33-824 to stimulate GH and prolactin (PRL) secretion and of exogenous GHRH to induce GH secretion. Human GH (25 and 250 micrograms bid for 4 days) administered to hypophysectomized rats strikingly reduced beta-EP and met-enk-like immunoreactivity (LI) in the medial basal hypothalamus, the effect being already maximal with the lower hGH dose. The higher dose of hGH diminished, though to a lower extent, hypothalamic beta EP-LI content also in intact rats, and reduced GHRH-LI content in the ME. Despite these profound biochemical alterations, the GH responsiveness to GHRH and FK 33-824 administration was preserved, while the latter drug induced a lower PRL rise in GH-treated than in control rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2957419     DOI: 10.1007/BF03348122

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Letter: Catecholamines in the median eminence: new evidence for a major noradrenergic input.

Authors:  A C Cuello; A S Horn; A V Mackay; L L Iversen
Journal:  Nature       Date:  1973-06-22       Impact factor: 49.962

2.  Modulation of somatostatin binding to rat pituitary membranes by exogenously administered growth hormone.

Authors:  H Katakami; M Berelowitz; M Marbach; L A Frohman
Journal:  Endocrinology       Date:  1985-08       Impact factor: 4.736

3.  Supersensitivity to opioids following the chronic blockade of endorphin action by naloxone.

Authors:  R Schulz; M Wüster; A Herz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-01       Impact factor: 3.000

4.  Prolonged hyperprolactinemia influences beta-endorphin and Met-enkephalin in the brain.

Authors:  A E Panerai; J Sawynok; F S LaBella; H G Friesen
Journal:  Endocrinology       Date:  1980-06       Impact factor: 4.736

5.  Selective actions of prolactin on catecholamine turnover in the hypothalamus and on serum LH and FSH.

Authors:  G A Gudelsky; J Simpkins; G P Mueller; J Meites; K E Moore
Journal:  Neuroendocrinology       Date:  1976       Impact factor: 4.914

6.  On the mechanism of growth hormone autofeedback regulation: possible role of somatostatin and growth hormone-releasing factor.

Authors:  S Conway; S M McCann; L Krulich
Journal:  Endocrinology       Date:  1985-12       Impact factor: 4.736

7.  Antibodies to growth hormone-releasing factor inhibit somatic growth.

Authors:  W B Wehrenberg; B Bloch; B J Phillips
Journal:  Endocrinology       Date:  1984-09       Impact factor: 4.736

8.  Hypothalamic neurotransmitter function in experimentally induced hyperprolactinemia.

Authors:  A Peñalva; A Novelli; M Parenti; V Locatelli; E E Müller; D Cocchi
Journal:  Brain Res       Date:  1984-12-24       Impact factor: 3.252

9.  Acromegaly associated with a bronchial carcinoid tumor: evidence for ectopic production of growth hormone-releasing activity.

Authors:  M Saeed uz Zafar; R C Mellinger; G Fine; M Szabo; L A Frohman
Journal:  J Clin Endocrinol Metab       Date:  1979-01       Impact factor: 5.958

10.  Beta-endorphin-induced decrease in hypothalamic dopamine turnover.

Authors:  G R van Loon; D Ho; C Kim
Journal:  Endocrinology       Date:  1980-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.